Are colonoscopies worth it?
New evidence from large randomized trials is calling into question how much routine colonoscopy screening actually reduces colon cancer deaths, especially in average‑risk adults, given the small absolute risk reduction and non‑trivial complication rates. Commenters weigh these statistical nuances against vivid personal stories of cancers caught (or missed), arguing over whether the benefits justify the risks, discomfort, cost, and heavy sedation often used in some countries. Many conclude that colorectal screening clearly helps when symptoms or strong family history are present, but that stool tests, DNA tests, or virtual imaging may be preferable first‑line options for the general population.
Overall effectiveness and the NordICC trial
- Discussion centers on the Nordic randomized trial: invitation to colonoscopy vs usual care in 55–64-year-olds over 10 years.
- Reported: ~18% relative reduction in colorectal cancer incidence; ~10% reduction in CRC mortality and ~1% in all-cause mortality, both statistically non‑significant.
- Strong debate on interpretation:
- One side: modest benefit at best, possibly poor ROI; other older, more favorable studies seen as lower quality.
- Other side: even small absolute reductions matter, especially in terms of avoided suffering, surgery, and chemo, not just death.
- Contention about per‑protocol vs intention‑to‑treat analyses and self‑selection bias (higher‑risk people more likely to accept colonoscopy). How much this inflates apparent benefit is disputed.
Risks and harms
- Known complications: perforation, major bleeding, anesthesia risks; estimates vary from ~3 perforations and ~15 major bleeds per 10,000 to negligible in some newer series.
- Some argue aggregate harm may outweigh modest population benefit; others note complications are rare compared with late-stage cancer morbidity.
- Non-trivial prep burden (fasting, laxatives, migraines for some) and possible microbiome disruption are raised but not well quantified.
Alternative screening methods
- Widely discussed options: FIT/FOBT, high-sensitivity stool tests, stool DNA tests (e.g., sDNA‑FIT/Cologuard), blood DNA assays, CT/MR “virtual colonoscopy”, capsule cameras.
- Pros: non‑invasive, cheaper, easier to scale; higher uptake in national programs.
- Cons: more false positives, lower sensitivity for precancerous polyps; positives usually lead to colonoscopy anyway.
- Several commenters suspect annual or biennial stool testing may have comparable or better benefit‑cost in average‑risk populations; evidence still incomplete/unclear.
Risk stratification and health‑system context
- Strong consensus that family history, genetic syndromes, or symptoms (bleeding, “funny tubes”) justify aggressive colonoscopy schedules.
- For average‑risk, asymptomatic people, the value is less clear and may depend on age and system costs (single‑payer vs US fee‑for‑service).
- Some highlight financial incentives and equipment sunk costs driving high colonoscopy use in certain countries.
Patient experience and practical issues
- Many report the prep as the worst part; the procedure itself is often a non‑event, especially with sedation.
- Others find unsedated scopes quite painful, or sedation itself unpleasant. Sedation intensity varies widely by country.
- Logistical barriers (time off work, transport, waitlists) significantly affect real‑world uptake.
Communication, terminology, and takeaways
- Debate over calling colonoscopy “invasive” and whether soft‑pedaling discomfort is ethical.
- Clear distinction urged between screening (asymptomatic) and diagnostic testing (symptomatic).
- Broad thread-level convergence:
- Screening for colorectal cancer in some form is worthwhile.
- The optimal modality and interval, especially for average‑risk people, remain genuinely uncertain.